1. Field of the Invention
The present invention relates to implantable medical devices and, more specifically, to medical devices that provide data to clinicians for analysis.
2. Description of the Related Art
There are numerous types of implantable medical devices (IMDs) that are available for gathering information and/or delivering therapy. In the cardiac arena, pacemakers (implantable pulse generators (IPGs)) and implantable cardioverter/defibrillators (ICDs) are the most common, and it should be appreciated that ICDs often also include pacing capabilities. The assignee of the present invention also makes an implantable loop recorder (ILM) that does not deliver any electrical therapy, but does monitor and record various cardiac signals. The IMDs will have a memory unit that stores certain types of information and transmits that information to an external device through a telemetry session for use and analysis.
When an IMD has pacing capabilities, that device is programmed to operate in a given mode. For example, a commonly used mode is referred to as DDD/R. This means that the IMD can sense and pace in multiple chambers of the heart (typically, the right atrium and right ventricle) and is rate responsive. The DDD/R mode is very comprehensive and provides for almost complete control of cardiac timing. After each atrial event (either intrinsic or paced), an AV interval (AVI) is started. At the end of the AVI, the device will deliver a ventricular pacing pulse, unless one has occurred intrinsically. However, since the DDD/R mode is comprehensive and attempts to provide a normalized cardiac cycle, the AVI is relatively short; thus, this almost always results in a ventricular pacing pulse occurring. In other words, a patient would need to have unusually fast intrinsic conduction time to have intrinsic ventricular depolarization when operating in a nominal DDD/R mode.
While the DDD/R mode is comprehensive and beneficial, there is a class of patients that have intact but “slow” AV conduction times. Thus, but for the setting of the AVI, the atrial event would naturally lead to the depolarization of the ventricles without having to provide ventricular pacing. There has been a recent recognition that allowing intrinsic conduction, even at longer intervals, is preferred to providing ventricular pacing. There are, of course, reasons why such pacing would be preferable or necessary. For example, a patient having complete heart block would be dependent upon ventricular pacing. Certain therapies, such as cardiac resynchronization therapy (CRT), pace both the left and right ventricles for heart failure patients.
As indicated, the recognition that ventricular pacing, particularly pacing in the right ventricular apex, is less desirable than permitting intrinsic conduction, is relatively recent. The assignee of the present invention has developed a mode that facilitates intrinsic conduction while providing ventricular pacing only when necessary. One commercial embodiment of this mode is referred to as the Managed Ventricular Pacing™ mode or the MVP™ mode. In this mode, a full cardiac cycle is permitted to elapse without providing ventricular pacing. Thus, for a given cycle, this affords the maximum amount of time for intrinsic conduction to occur. If no ventricular activity occurs in a given cycle, pacing is provided in the subsequent cycle; and, if this occurs too frequently (e.g., 2 out 4 cycles), then ventricular pacing in a standard mode (e.g., DDD/R) is provided for a period of time. Periodic conduction checks are performed to determine if intrinsic conduction has returned, as such block is often transient in patients. This discussion is meant to be exemplary and illustrative and in no way limiting of the MVP™ mode or other modes.
There are other modes that seek to extend or maximize duration during which intrinsic conduction is permitted. Some of these modes do not permit a complete cardiac cycle to transpire without ventricular activity, but provide the longest permissible AV interval such that a delivered ventricular pace will not adversely interfere with the subsequent atrial event (from a timing perspective). As used herein, these modes are collectively referred to as atrial-based pacing mode. In short, atrial-based pacing modes utilize A-A intervals to determine and/or control cardiac rate and seek to limit ventricular pacing by either tolerating a cycle devoid of ventricular activity or providing a relatively long AV interval as compared with standard DDD modes.
With atrial-based pacing, the atrial rate is known or knowable, but the actual AV delay is generally not known for a given cycle, as intrinsic conduction can occur at various times. The maximum variability occurs in modes that tolerate an absence of ventricular activity for a given cycle, as the actual AV delay may be equal to or any value less than the A-A interval, or there may not be a value for a given cycle. Comparing this to standard DDD/R timing, a typical AVI may be on the order of 150 ms, as an example. Thus, the AV delay could be 0-150 ms and, in practice, very short delays are likely to be PVCs, and thus, the range is 80-150 ms. In an atrial-based mode tolerating absent ventricular cycles, at a rate of 60 bpm, the AV delay may be 0-1000 ms. Thus, in atrial-based pacing modes the range of timing is greatly expanded.
The IMD 10 provides data to and/or receives information from an external medical device (EMD) 50. EMD 50 may be a medical device programmer, an in-home monitor or a personal communication device such as a wireless phone, pager, or the like. As illustrated, the EMD 50 serves to communicate with the IMD 10 and transmit information to a remote server 60, such as the Medtronic CareLink™ Network. Information from the server 60 may then be accessed at a user's computing device 70, and information 80 from and about the IMD 10 is displayed and/or printed. In the case of a medical device programmer or a device reader, one- or two-way communication with the IMD 10 may occur without subsequent communication from the EMD 50 to another device and the information 80 could be displayed on or obtained from the EMD 50.
As discussed, the IMD 10 is operable in an atrial-based pacing mode. That is, atrial pacing is provided as needed; however, ventricular pacing is reduced or minimized. In other words, the patient's natural conduction is permitted to depolarize the ventricles, despite what may normally be considered “long” AV delays. As both atrial and ventricular activity is sensed, the resultant timing is known. Thus, AV delays are measured and stored in the memory of the IMD 10. This data may be telemetered out and analyzed as discussed herein.
Various sample data sets are provided, such as how much AT/AF occurs in a given day, the ventricular rate during these events, percentage of pacing and an average ventricular rate. These data sets simply illustrate various cardiac parameters that can be represented in graphical form over time and do not represent actual or even correlated data.
Data subset 100 is a graph that illustrates the patient's AV delay in milliseconds (Y axis) over time (X axis). Such data is relevant, assuming the patient does not have complete heart block (e.g., is pacemaker dependent) and is operating in an atrial-based pacing mode so that the intrinsic conduction timing is permitted to emerge. As used herein, the AV delay is relevant over a consistent heart rate. That is, as heart rate changes, the AV delay is expected to change. Thus, the data subset 100 is provided for a given heart rate or rate range. Though not shown, similar data may be provided for multiple rates or rate ranges.
As indicated, the AV delay data is presented for a given heart rate. Multiple values for different heart rates may be collected and displayed. This will tend to illustrate conditions that are more prevalent at specific heart rates. As the patient's heart rate fluctuates normally, it may be difficult to obtain measurements at a specific predetermined value. Thus, the IMD 10 can be programmed to pace at the desired rate at a given interval (e.g., four times per day at 60 bpm) for a sufficiently long period of time such that the underlying conduction emerges. Naturally, the test would be postponed or cancelled based upon patient need. For example, if the patient is strenuously exercising, the IMD 10 will not alter the heart rate from, e.g., 130 bpm to 60 bpm, simply for data collection. Furthermore, the activity sensor may be utilized to determine periods of rest and/or sleep. This determination may be used to identify time to pace at specific rates. Alternatively, rather than forcing a specific rate, the rate may be noted and data collected at the resting rate.
Trending of AV delay data 100 can illustrate various aspects of the patient's condition. Assuming the patient is generally healthy, the AV delay should remain relatively constant (with normal fluctuations for variation due to rate being normal). Patients may experience period of intermittent heart block and this will be represented as the device delivers ventricular pacing. Assuming the frequency of such occurrences is tolerable, the caregiver may deem the condition acceptable.
As indicated, normal progression of AV nodal sickness is gradual over time. More rapid increases and/frequent changes to AV delay is indicative of other issues for the patient. Specifically, what those issues are will vary, and may be determined from the context provided by additional information accessible to the caregiver. For example, the device report 80 may include other cardiac data that provides the appropriate contextual information. Other information, in context, may be provided by alternative mechanisms. For example, the patient's medical record may be reviewed, the electronic medical record (EMR) may be delivered, the device report 80 may be modified to include information from the EMR, and of course, the caregiver may have their own knowledge of the patient from which to draw upon. The mechanism for providing information in context for disease management is described in co-pending applications (U.S. patent application Ser. No. 11/038,814 filed Jan. 20, 2005; and U.S. patent application Ser. No. 11/038,835 filed Jan. 20, 2005), which are herein incorporated by reference in their entirety. Thus, what the AV delay trends indicate is not meant to be a limiting factor of the present invention.
With the data provided, the caregiver can evaluate the AV delay information and determine if there is a cyclic correlation between the changes and other events. For example, the patient might experience prolonged AV delays after delivery of therapy for ventricular tachycardia. The caregiver could determine if this is a concern and, if so, the IMD 10 could be programmed to operate in a standard mode for a corresponding period of time after such therapy is delivered.
A patient's balance or level of electrolytes is known to affect AV delays. Thus, the caregiver may determine that the changes in AV delay represent an imbalance in electrolytes with potential causes including dehydration, diabetes, and the effects of various medications. Thus, the patient may be advised to consume fluids, manage their diabetes through dietary or medicinal modifications (or simply to follow their prescribed regime if not doing so diligently), or titrating or replacing the various medications. Patients having renal disease often have dialysis as a treatment. Changes in the AV delay may be associated with the effectiveness of this treatment and the state of the disease. Thus, AV delay data may be an indication that, for example, dialysis should occur more frequently. Another condition affecting AV delay is infarction occurring in certain areas of the heart. Thus, the AV delay data may lead the caregiver to investigate this as an issue. Furthermore, the AV delay data may be correlated to patient complaints of angina, which would further suggest an infarct. Lyme disease has been known in certain circumstances to affect AV delay. Acute changes in blood pressure can lead to conduction irregularities. Thus, the AV delay data may be correlated to such pressure fluctuation (which may otherwise be unmeasured). The hypertension may then be treated; alternatively, acute hypertension may be caused by arterial insult or injury, including obstructions. Thus, these potentially serious matters may be diagnosed after the initial AV delay data indicates that issues are present. In other words, the AV delay data may in and of itself permit a caregiver to diagnose a condition and prescribe a therapy or corrective action; the AV delay data combined with other data in context may provide the same result; and the AV delay data may indicate that an issue exists that is undeterminable from the current data, which leads the caregiver to investigate further. Once again, these examples are not meant to be limiting.
Another use of the AV delay trend data set is as a correlative trigger for data collection. Implantable medical devices have limited memory capacity. Thus, certain devices may not be able to record complete data sets for extended periods of time. These devices sometime include an external patient activator. When the patient has specific symptoms, they utilize the activator, which causes the IMD to record the relevant data set for the time period including the patient-indicated symptoms. In some cases, the patient may not perceive any symptoms when a particular condition is occurring or may be unable to utilize the activator, either because they are physically unable, or simply do not have the activator with them. Thus, the AV delay data may correlate to the conditions of interest to the caregiver. As such, when the AV delay reaches a particular level or varies at a particular rate of change (e.g., slope) then the IMD is triggered to store additional data.
As used herein, the AV delay refers to the interval between any atrial event and any ventricular event. The data is only meaningful if the ventricular events are generally intrinsic. That is, a certain number of ventricular pacing pulses (fixed AV interval) will still result in useful averaged data; however, if pacing continuously in the ventricles, this data loses its value. As such, the IMD 10 may exclude data resulting from a ventricular pace. Alternatively, such data may be included with or without specifically identifying its effect on the average. Similarly, the AV delay data may be presented as a combination or split between events triggered from an atrial pace (Ap-Vs) and events triggered from intrinsic atrial depolarization (As-Vs). As one can appreciate, such data may be presented to a user in any number of formats.
The AV delay data is presented in an appropriate form to a caregiver who evaluates (400) the data, as indicated in
When the AV delay data is evaluated (400), the caregiver determines if any issue is raised by the data (410). If not, the process returns and the caregiver re-evaluates the data (400) at the next appropriate time interval. Conversely, if the data does indicate that an issue exists, the caregiver determines if he or she has sufficient information to evaluate and act upon the data (420). If there is insufficient data, the caregiver will obtain additional information and/or make an evaluation based upon their medical judgment (430). Such additional information may be obtained from journals and databases, patient records, or patient communication. Furthermore, the data itself may be insufficient and require additional evaluation and/or testing of the patient, which may be scheduled and performed.
Once the caregiver has diagnosed the patient, the caregiver determines if there is an appropriate course of action (440). In some cases, no action is required or available; thus, the process reverts to step 400 and the data continues to be monitored. If an appropriate course of action is identified (440), that action is then performed (450). As indicated, such actions may include adjusting device parameters, titrating medication, prescribing medication, eliminating the use of a medication, adjusting diet or other patient behavior, increasing/modifying dialysis, modifying the parameters of another medical device (e.g., insulin drug pump, CPAP machine), or performing other medical procedures (e.g., bypass operation, stent implantation).
Thus, AV delay data is monitored and provided to a caregiver. The trending of this data over short or long periods of time may be indicative of various patient conditions when an atrial-based pacing mode is selected. The selection of an atrial-based pacing mode provides a sufficient time window for intrinsic conduction to occur and provide meaningful data, which would otherwise be unavailable with predefined nominal AV pacing intervals such as those used in the DDD/R mode.
This application is a continuation of U.S. patent application Ser. No. 11/336,753, filed Jan. 20, 2006 entitled “SYSTEM AND METHOD OF USING AV CONDUCTION TIMING”, herein incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3057356 | Greatbatch | Oct 1962 | A |
3253596 | Keller | May 1966 | A |
3478746 | Greatbatch | Nov 1969 | A |
3595242 | Berkovits | Jul 1971 | A |
3648707 | Greatbatch | Mar 1972 | A |
3747604 | Berkovits | Jul 1973 | A |
4312355 | Funke | Jan 1982 | A |
4386610 | Leckrone | Jun 1983 | A |
4428378 | Anderson et al. | Jan 1984 | A |
4432362 | Leckrone et al. | Feb 1984 | A |
4476868 | Thompson | Oct 1984 | A |
4523593 | Rueter et al. | Jun 1985 | A |
4577633 | Berkovits et al. | Mar 1986 | A |
4587970 | Holley et al. | May 1986 | A |
4726380 | Vollmann et al. | Feb 1988 | A |
4727877 | Kallok | Mar 1988 | A |
4856523 | Sholder et al. | Aug 1989 | A |
4856524 | Baker | Aug 1989 | A |
4880005 | Pless et al. | Nov 1989 | A |
4890617 | Markowitz et al. | Jan 1990 | A |
4932046 | Katz et al. | Jun 1990 | A |
4941471 | Mehra | Jul 1990 | A |
4953551 | Mehra et al. | Sep 1990 | A |
5052388 | Sivula et al. | Oct 1991 | A |
5085215 | Nappholz et al. | Feb 1992 | A |
5097832 | Buchanan | Mar 1992 | A |
5117824 | Keimel et al. | Jun 1992 | A |
5133350 | Duffin | Jul 1992 | A |
5144950 | Stoop et al. | Sep 1992 | A |
5163427 | Keimel | Nov 1992 | A |
5188105 | Keimel | Feb 1993 | A |
5188117 | Steinhaus et al. | Feb 1993 | A |
5228438 | Buchanan | Jul 1993 | A |
5273035 | Markowitz et al. | Dec 1993 | A |
5292340 | Crosby et al. | Mar 1994 | A |
5318594 | Limousin et al. | Jun 1994 | A |
5334220 | Sholder | Aug 1994 | A |
5345362 | Winkler | Sep 1994 | A |
5372607 | Stone et al. | Dec 1994 | A |
5388586 | Lee et al. | Feb 1995 | A |
5417714 | Levine et al. | May 1995 | A |
5522859 | Stroebel et al. | Jun 1996 | A |
5540725 | Bornzin et al. | Jul 1996 | A |
5584868 | Salo et al. | Dec 1996 | A |
5591214 | Lu | Jan 1997 | A |
5626623 | Kieval et al. | May 1997 | A |
5643326 | Weiner et al. | Jul 1997 | A |
5674257 | Stroebel et al. | Oct 1997 | A |
5697958 | Paul et al. | Dec 1997 | A |
5725561 | Stroebel et al. | Mar 1998 | A |
5741308 | Sholder et al. | Apr 1998 | A |
5755737 | Prieve et al. | May 1998 | A |
5814077 | Sholder et al. | Sep 1998 | A |
5836974 | Christini et al. | Nov 1998 | A |
5861007 | Hess et al. | Jan 1999 | A |
5873895 | Sholder et al. | Feb 1999 | A |
5954755 | Casavant | Sep 1999 | A |
5999850 | Dawson et al. | Dec 1999 | A |
6045513 | Stone et al. | Apr 2000 | A |
6058326 | Hess et al. | May 2000 | A |
6122546 | Levine et al. | Sep 2000 | A |
6128529 | Esler et al. | Oct 2000 | A |
6128534 | Park et al. | Oct 2000 | A |
6141586 | Mower | Oct 2000 | A |
6169918 | Haefner et al. | Jan 2001 | B1 |
6198968 | Prutchi et al. | Mar 2001 | B1 |
6256541 | Heil et al. | Jul 2001 | B1 |
6321115 | Mouchawar et al. | Nov 2001 | B1 |
6397105 | Bouhour et al. | May 2002 | B1 |
6434424 | Igel et al. | Aug 2002 | B1 |
6477416 | Florio et al. | Nov 2002 | B1 |
6609028 | Struble | Aug 2003 | B2 |
6654637 | Rouw et al. | Nov 2003 | B2 |
6697673 | Lu | Feb 2004 | B1 |
6731980 | Mouchawar et al. | May 2004 | B1 |
6772005 | Casavant et al. | Aug 2004 | B2 |
6792307 | Levine et al. | Sep 2004 | B1 |
6873875 | Gilkerson et al. | Mar 2005 | B1 |
6904315 | Panken et al. | Jun 2005 | B2 |
6925326 | Levine et al. | Aug 2005 | B1 |
6978175 | Florio et al. | Dec 2005 | B1 |
7027868 | Rueter et al. | Apr 2006 | B2 |
7123960 | Ding et al. | Oct 2006 | B2 |
7130683 | Casavant et al. | Oct 2006 | B2 |
7218965 | Casavant et al. | May 2007 | B2 |
7245966 | Betzold et al. | Jul 2007 | B2 |
7248924 | Casavant | Jul 2007 | B2 |
7254441 | Stroebel | Aug 2007 | B2 |
7283872 | Boute et al. | Oct 2007 | B2 |
7925344 | Condie | Apr 2011 | B2 |
20020038482 | Mennicke et al. | Apr 2002 | A1 |
20020041700 | Therbaud | Apr 2002 | A1 |
20020062139 | Ding | May 2002 | A1 |
20020082646 | Casavant et al. | Jun 2002 | A1 |
20020128687 | Baker et al. | Sep 2002 | A1 |
20020138417 | Lawrence | Sep 2002 | A1 |
20030078627 | Casavant et al. | Apr 2003 | A1 |
20040010292 | Amblard et al. | Jan 2004 | A1 |
20040024694 | Lawrence et al. | Feb 2004 | A1 |
20040078321 | Lawrence | Apr 2004 | A1 |
20040117316 | Gillum | Jun 2004 | A1 |
20040162466 | Quy | Aug 2004 | A1 |
20040260349 | Stroebel | Dec 2004 | A1 |
20050038482 | Yonce et al. | Feb 2005 | A1 |
20050055059 | Betzold et al. | Mar 2005 | A1 |
20050096708 | Seim et al. | May 2005 | A1 |
20050177197 | Betzold | Aug 2005 | A1 |
20050267539 | Betzold et al. | Dec 2005 | A1 |
20050273430 | Pliha | Dec 2005 | A1 |
20070203523 | Betzold | Aug 2007 | A1 |
20070213777 | Betzold et al. | Sep 2007 | A1 |
Number | Date | Country |
---|---|---|
0363015 | Apr 1990 | EP |
0448193 | Sep 1991 | EP |
0624386 | Nov 1994 | EP |
0830877 | Mar 1998 | EP |
1449562 | Aug 2004 | EP |
WO 9532758 | Dec 1995 | WO |
WO 02051499 | Jul 2002 | WO |
WO 2005097259 | Oct 2005 | WO |
WO 2005113065 | Dec 2005 | WO |
WO 2006079037 | Jul 2006 | WO |
WO 2006079066 | Jul 2006 | WO |
Number | Date | Country | |
---|---|---|---|
20110184299 A1 | Jul 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11336753 | Jan 2006 | US |
Child | 13078536 | US |